An-Sofie Viskens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
An-Sofie Viskens has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Adam M. Chaker
Department of Otorhinolaryngology and Center for Allergy and Environment (ZAUM), TUM School of Medicine and Health, TUM University Hospital, Klinikum Rechts der Isar Technical University of Munich Munich Germany
2 shared publications - Anju Tripathi Peters
Division of Allergy and Immunology Feinberg School of Medicine Northwestern University Chicago Illinois USA
2 shared publications Brent Senior
Department of Otolaryngology/Head and Neck Surgery University of North Carolina Chapel Hill North Carolina USA
2 shared publications- Carl Philpott
Department of Otolaryngology James Paget University Hospital NHS Foundation Trust Great Yarmouth UK
2 shared publications - Dermot Ryan
Usher Institute University of Edinburgh Edinburgh UK
2 shared publications Elina Toskala
Otolaryngology‐HNS Thomas Jefferson University Philadelphia Pennsylvania USA
2 shared publications
Latest Publications
- 4 September 2025
- Published by University of Antwerp
Towards better chronic rhinosinusitis care by investigating novel therapeutic approaches that modulate the mucosal epithelial barrier
Chronic rhinosinusitis (CRS) is a prevalent and debilitating inflammatory condition of the nasal and paranasal sinuses, with multifactorial and often ill-defined pathophysiology, leading to major quality-of-life impairments. Current therapies largely aim at symptom control rather than remission or cure, leaving many patients with uncontrolled disease. This doctoral thesis sought to improve CRS care by identifying 1) characterizing the reasons for uncontrolled disease, 2) evaluating the real-world efficacy of two therapeutic molecules omalizumab and mepolizumab for CRSwNP, 3) examining epithelial and immunological responses to dupilumab to explore the disease-modifying effect and 4) investigating the effects of an INCS molecule on Covid-related immune effects on the epithelial barrier. We highlighted the impact of epithelial barrier dysfunction in uncontrolled disease, hence supporting the need to consider disease-modifying treatments in the future. We confirmed the effects of biologicals and showed barrier restoring and potential disease-modifying effects of dupilumab. Furthermore, we showed a potential role for the restoration of the nasal epithelial barrier as a preventive strategy against viral infections.
- 4 September 2025
- Published by University of Antwerp
Towards better chronic rhinosinusitis care by investigating novel therapeutic approaches that modulate the mucosal epithelial barrier
Chronic rhinosinusitis (CRS) is a prevalent and debilitating inflammatory condition of the nasal and paranasal sinuses, with multifactorial and often ill-defined pathophysiology, leading to major quality-of-life impairments. Current therapies largely aim at symptom control rather than remission or cure, leaving many patients with uncontrolled disease. This doctoral thesis sought to improve CRS care by identifying 1) characterizing the reasons for uncontrolled disease, 2) evaluating the real-world efficacy of two therapeutic molecules omalizumab and mepolizumab for CRSwNP, 3) examining epithelial and immunological responses to dupilumab to explore the disease-modifying effect and 4) investigating the effects of an INCS molecule on Covid-related immune effects on the epithelial barrier. We highlighted the impact of epithelial barrier dysfunction in uncontrolled disease, hence supporting the need to consider disease-modifying treatments in the future. We confirmed the effects of biologicals and showed barrier restoring and potential disease-modifying effects of dupilumab. Furthermore, we showed a potential role for the restoration of the nasal epithelial barrier as a preventive strategy against viral infections.
- Top Cited PapersOpen Access
EUFOREA/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care
Following the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) treatment algorithm for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), patients suffering from severe uncontrolled CRSwNP are recommended to receive oral corticosteroids, (revision) sinus surgery, systemic biologicals and/or aspirin treatment after desensitization (ATAD). Given the major differences in indications, outcomes, practical considerations, risks and costs of these key pillars of treatment, there is a growing need to define criteria for each treatment option and list the clinically relevant and major considerations for them. This EUFOREA document therefore provides an expert panel overview of the expected outcomes, specific considerations and (contra)indications of the five major treatment arms of severe uncontrolled CRSwNP: oral corticosteroids, primary and revision sinus surgery, biological treatment and ATAD. This overview of treatment considerations is needed to allow physicians and patients to consider the different options in the context of providing optimal and personalized care for severe uncontrolled CRSwNP. In conclusion, the five major treatment options for severe uncontrolled CRSwNP have intrinsic advantages, specific indications and considerations that are of importance to the patient, the physician and the society. This EUFOREA statement supports the unmet need to define criteria for the indication of every treatment pillar of CRSwNP.
Top Cited PapersOpen AccessEUFOREA/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care
Following the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) treatment algorithm for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), patients suffering from severe uncontrolled CRSwNP are recommended to receive oral corticosteroids, (revision) sinus surgery, systemic biologicals and/or aspirin treatment after desensitization (ATAD). Given the major differences in indications, outcomes, practical considerations, risks and costs of these key pillars of treatment, there is a growing need to define criteria for each treatment option and list the clinically relevant and major considerations for them. This EUFOREA document therefore provides an expert panel overview of the expected outcomes, specific considerations and (contra)indications of the five major treatment arms of severe uncontrolled CRSwNP: oral corticosteroids, primary and revision sinus surgery, biological treatment and ATAD. This overview of treatment considerations is needed to allow physicians and patients to consider the different options in the context of providing optimal and personalized care for severe uncontrolled CRSwNP. In conclusion, the five major treatment options for severe uncontrolled CRSwNP have intrinsic advantages, specific indications and considerations that are of importance to the patient, the physician and the society. This EUFOREA statement supports the unmet need to define criteria for the indication of every treatment pillar of CRSwNP.
- Open Access
- 24 October 2023
- Published by Wiley
EUFOREA/EPOS2020 Statement on the Clinical Considerations for CRSwNP Care
Following the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) treatment algorithm for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), patients suffering from severe uncontrolled CRSwNP are recommended to receive oral corticosteroids, (revision) sinus surgery, systemic biologicals, and/or aspirin treatment after desensitization (ATAD). Given the major differences in indications, outcomes, practical considerations, risks and costs of these key pillars of treatment, there is a growing need to define criteria for each treatment option and list the clinically relevant and major considerations for them. This EUFOREA document therefore provides an expert panel overview of the expected outcomes, specific considerations and (contra)indications of the five major treatment arms of severe uncontrolled CRSwNP: oral corticosteroids, primary and revision sinus surgery, biological treatment, and ATAD. This overview of treatment considerations is needed to allow physicians and patients to consider the different options in the context of providing optimal and personalized care for severe uncontrolled CRSwNP. In conclusion, the five major treatment options for severe uncontrolled CRSwNP have intrinsic advantages, specific indications, and considerations that are of importance to the patient, the physician, and the society. This EUFOREA statement supports the unmet need to define criteria for the indication of every treatment pillar of CRSwNP.
- 24 October 2023
- Published by Wiley
Open AccessEUFOREA/EPOS2020 Statement on the Clinical Considerations for CRSwNP Care
Following the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) treatment algorithm for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), patients suffering from severe uncontrolled CRSwNP are recommended to receive oral corticosteroids, (revision) sinus surgery, systemic biologicals, and/or aspirin treatment after desensitization (ATAD). Given the major differences in indications, outcomes, practical considerations, risks and costs of these key pillars of treatment, there is a growing need to define criteria for each treatment option and list the clinically relevant and major considerations for them. This EUFOREA document therefore provides an expert panel overview of the expected outcomes, specific considerations and (contra)indications of the five major treatment arms of severe uncontrolled CRSwNP: oral corticosteroids, primary and revision sinus surgery, biological treatment, and ATAD. This overview of treatment considerations is needed to allow physicians and patients to consider the different options in the context of providing optimal and personalized care for severe uncontrolled CRSwNP. In conclusion, the five major treatment options for severe uncontrolled CRSwNP have intrinsic advantages, specific indications, and considerations that are of importance to the patient, the physician, and the society. This EUFOREA statement supports the unmet need to define criteria for the indication of every treatment pillar of CRSwNP.